Comparative Pharmacology
Head-to-head clinical analysis: NORDETTE 28 versus NORETHIN 1 50M 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORDETTE 28 versus NORETHIN 1 50M 21.
NORDETTE-28 vs NORETHIN 1/50M-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combined estrogen-progestin oral contraceptive. Suppresses gonadotropin (FSH, LH) release from pituitary, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial lining.
Norethindrone is a progestin that suppresses gonadotropin release from the pituitary, inhibiting ovulation. It also induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
One tablet orally once daily for 28 consecutive days.
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (mean 17 hours); Levonorgestrel: 11-45 hours (mean 24 hours); clinical context: steady-state reached after 5-7 days.
Terminal elimination half-life: 5-14 hours (mean ~8h). Clinical context: Steady-state achieved after 4-5 days; dosing interval 24 hours maintains therapeutic levels.
Renal: ~50% as metabolites, ~20% unchanged; Fecal: ~30% as metabolites; Biliary: minimal.
Renal: 50-60% as metabolites; Fecal: 30-40% (via biliary); Less than 5% unchanged in urine.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive